Knight Therapeutics (TSE:GUD) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Knight Therapeutics Inc. successfully concluded its Annual General Meeting, with all director nominees from the Management Information Circular being elected with high approval rates. Additionally, Ernst & Young LLP were appointed as external auditors with overwhelming shareholder support, and a resolution to renew unallocated rights under the Omnibus Equity Incentive Plan was approved by a significant majority.
For further insights into TSE:GUD stock, check out TipRanks’ Stock Analysis page.